Trials / Completed
CompletedNCT01102946
Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy
Panretinal Photocoagulation Versus Panretinal Photocoagulation Plus Intravitreous Ranibizumab for High Risk Proliferative Diabetic Retinopathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- University of Sao Paulo · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effects of panretinal photocoagulation plus intravitreal ranibizumab for the treatment of patients with high risk proliferative diabetic retinopathy in terms of changes in visual acuity and neovascularization area.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab | Ranibizumab (Lucentis), intravitreal injections of 0.05ml |
| PROCEDURE | Panretinal Photocoagulation | Panretinal photocoagulation with green laser according to ETDRS |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2010-04-13
- Last updated
- 2011-08-04
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT01102946. Inclusion in this directory is not an endorsement.